$NUVB

$6.00▲ +4.2% YTD

3 SEC 13D/G filings tracked · Last updated Sep 17, 2026

Filing History

CP $6.00▲ +4.2%Sep 17, 2026 · ThinkSabio Blog

$NUVB - Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI…

News

NUVB ▼ -0.5% - Nuvation Bio Inc.

CP $5.90▲ -0.5%Sep 15, 2026 · ThinkSabio Blog

$NUVB - Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in A…

News

NUVB ▲ +3.7% - Nuvation Bio Inc.

CP $6.93▲ +3.7%Sep 2, 2026 · ThinkSabio Blog

$NUVB - Nuvation Bio to Participate in Upcoming Investor Conferences…